Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Key Points

• Wells Fargo raised its price target on Travere from $40 to $50 and kept an "overweight" rating, joining other firms boosting targets (TD Cowen $60, Citigroup $59) while MarketBeat's consensus remains a Moderate Buy with a $47.83 average target.
• Q1 results were mixed: the company posted an EPS beat ($0.05 vs. -$0.24 est.) but missed revenue ($127.2M vs. ~$136.2M), though revenue grew ~55.6% year‑over‑year.
• Insiders sold roughly 310,852 shares (about $11.9M) last quarter — largely via pre‑arranged Rule 10b5‑1 plans — even as management points to operational catalysts like FDA approval of FILSPARI and resumed Phase 3 dosing for pegtibatinase.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) had its price objective hoisted by equities research analysts at Wells Fargo & Company from $40.00 to $50.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Wells Fargo & Company's target price points to a potential upside of 14.58% from the company's current price.

Several other brokerages have also recently commented on TVTX. Wall Street Zen cut shares of Travere Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 21st. Citigroup boosted their target price on Travere Therapeutics from $53.00 to $59.00 and gave the stock a "buy" rating in a research report on Tuesday. Canaccord Genuity Group boosted their target price on Travere Therapeutics from $47.00 to $56.00 and gave the stock a "buy" rating in a research report on Tuesday, April 14th. TD Cowen boosted their target price on Travere Therapeutics from $45.00 to $60.00 and gave the stock a "buy" rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. decreased their target price on Travere Therapeutics from $44.00 to $41.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 25th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Travere Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $47.83.

Travere Therapeutics Price Performance

TVTX stock traded down $1.16 during midday trading on Wednesday, hitting $43.64. The company's stock had a trading volume of 431,924 shares, compared to its average volume of 2,143,451. Travere Therapeutics has a 12 month low of $13.88 and a 12 month high of $48.61. The company has a quick ratio of 2.70, a current ratio of 2.74 and a debt-to-equity ratio of 2.71. The firm has a market capitalization of $4.03 billion, a price-to-earnings ratio of -189.91 and a beta of 1.13. The company has a 50 day moving average of $32.31 and a two-hundred day moving average of $32.71.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.29. The business had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. Travere Therapeutics had a negative return on equity of 28.38% and a negative net margin of 4.00%.The firm's revenue for the quarter was up 55.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.47) EPS. On average, analysts expect that Travere Therapeutics will post -0.16 EPS for the current year.

Insider Activity at Travere Therapeutics

In other Travere Therapeutics news, insider Elizabeth E. Reed sold 44,715 shares of the stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $41.21, for a total transaction of $1,842,705.15. Following the transaction, the insider directly owned 111,996 shares in the company, valued at $4,615,355.16. This represents a 28.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Sandra Calvin sold 21,977 shares of the stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $41.07, for a total transaction of $902,595.39. Following the transaction, the chief accounting officer owned 42,353 shares in the company, valued at approximately $1,739,437.71. The trade was a 34.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 310,852 shares of company stock worth $11,890,666 over the last quarter. Corporate insiders own 4.44% of the company's stock.

Institutional Investors Weigh In On Travere Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Arizona State Retirement System lifted its stake in shares of Travere Therapeutics by 1.5% during the 3rd quarter. Arizona State Retirement System now owns 24,964 shares of the company's stock worth $597,000 after purchasing an additional 375 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Travere Therapeutics by 69.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company's stock worth $45,000 after purchasing an additional 487 shares during the last quarter. Comerica Bank lifted its stake in shares of Travere Therapeutics by 77.5% during the 4th quarter. Comerica Bank now owns 1,127 shares of the company's stock worth $43,000 after purchasing an additional 492 shares during the last quarter. ProShare Advisors LLC lifted its stake in shares of Travere Therapeutics by 4.1% during the 4th quarter. ProShare Advisors LLC now owns 19,007 shares of the company's stock worth $726,000 after purchasing an additional 756 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Travere Therapeutics by 26.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,348 shares of the company's stock worth $166,000 after purchasing an additional 902 shares during the last quarter.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target to $60 and maintained a Buy rating, signaling >30% upside vs. recent levels and offering bullish analyst support for the stock. TD Cowen raises target to $60 (Benzinga)
• Positive Sentiment: Corporate update: management highlighted the FDA approval of FILSPARI in FSGS, strong demand for FILSPARI in IgAN, and the resumption of patient dosing in the pegtibatinase Phase 3 HARMONY study — operational catalysts that support longer‑term revenue upside. Travere Therapeutics Reports First Quarter 2026 Financial Results (BusinessWire)
• Neutral Sentiment: Q1 results were mixed: EPS beat (reported $0.05 vs. consensus -$0.24) but revenue missed ($127.2M vs. ~$136.2M est). Revenue growth was strong year-over-year (~+55.6%), but the top-line miss gives investors a reason to be cautious near-term. Q1 2026 press release / slide deck
• Neutral Sentiment: HC Wainwright kept a Buy rating and a $57 target but trimmed long‑range EPS forecasts modestly for FY2027–FY2030 (small downgrades to FY2027–2030 numbers). The firm’s continued Buy stance tempers the impact of the small cuts.
• Negative Sentiment: Insider selling: Director Roy Baynes sold 9,750 shares under a pre-arranged Rule 10b5‑1 plan (avg. ~$44.22). While disclosed as plan-based (reducing governance concern), the trade can still put short-term pressure on sentiment. SEC Form 4 (Roy Baynes sale)

About Travere Therapeutics

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.